Pharmaceutical Position Paper 2014/2015 - 制药工作组建议书2014/2015 Go back »


The Pharmaceutical Working Group represents 47 foreign pharmaceutical manufacturing companies operating in China. The working group encourages government policies that support the creation of a sustainable system that fosters innovation and healthy growth of the pharmaceutical industry as a whole, while improving patient access to innovative, high quality medicines, in line with China's declared strategic objectives for the healthcare sector. Policies related to intellectual property, pricing and reimbursement are the most potentially useful tools for rewarding quality and safety while creating incentives for domestic and multinational companies alike to bring innovative medicines to the Chinese market. The working group supports the establishment of a transparent regulatory environment to solicit comments and participation from the pharmaceutical industry (both local and foreign) before formal policy announcements involving such issues as pricing, reimbursement and intellectual property rights (IPR).

Related documents

Pharmaceutical Position Paper 2013/2014 - 制药建议书 2013/2014

Pharmaceutical Position Paper 2015/2016 - 制药工作组建议书2015/2016

Annual Working Group Report 2016 Pharmaceutical

Related EURObiz articles